Versor Investments LP Takes $396,000 Position in Inari Medical, Inc. (NASDAQ:NARI)

Versor Investments LP purchased a new stake in Inari Medical, Inc. (NASDAQ:NARI) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 9,600 shares of the company’s stock, valued at approximately $396,000.

Several other large investors have also recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in shares of Inari Medical by 164.7% during the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after purchasing an additional 438 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after purchasing an additional 435 shares during the period. Covestor Ltd raised its stake in Inari Medical by 30.2% during the first quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after buying an additional 376 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in Inari Medical by 39.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after buying an additional 522 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Inari Medical during the second quarter worth $104,000. 90.98% of the stock is owned by institutional investors.

Inari Medical Trading Down 3.0 %

Shares of NASDAQ NARI opened at $49.24 on Friday. The firm has a 50 day moving average of $45.09 and a 200 day moving average of $46.85. The firm has a market capitalization of $2.88 billion, a price-to-earnings ratio of -36.47 and a beta of 0.96. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $67.13.

Insiders Place Their Bets

In related news, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the sale, the director now owns 601,233 shares of the company’s stock, valued at $27,067,509.66. This represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now directly owns 445,310 shares in the company, valued at approximately $22,265,500. This represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 126,000 shares of company stock worth $5,921,390 over the last three months. 10.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have weighed in on NARI. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Inari Medical in a research note on Friday, August 9th. They issued a “buy” rating and a $68.00 price target for the company. Robert W. Baird boosted their target price on shares of Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, October 29th. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. William Blair started coverage on shares of Inari Medical in a research report on Thursday, July 25th. They issued an “outperform” rating on the stock. Finally, Wells Fargo & Company decreased their target price on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $58.89.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.